Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
Public ClinicalTrials.gov record NCT02722304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic obstructive pulmonary disease (COPD).
Study identification
- NCT ID
- NCT02722304
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 7 participants
Conditions and interventions
Interventions
- ARALAST NP 60 mg/kg Biological
- ARALAST NP 120 mg/kg Biological
- GLASSIA 60 mg/kg Biological
- GLASSIA 120 mg/kg Biological
- Human Albumin 2% Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2016 (Actual)
- Primary completion
- Sep 14, 2018 (Actual)
- Completion
- Sep 14, 2018 (Actual)
- Last update posted
- May 13, 2021
2016 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Medical Research Institute, LLC | Peoria | Arizona | 85381 | — |
| Newport Native MD, Inc | Newport Beach | California | 92663 | — |
| Pulmonary Disease Specialists, P.A., / PDS Research | Kissimmee | Florida | 34741 | — |
| L&C Professional Medical Research Institute | Miami | Florida | 33144 | — |
| Loyola University Health System | Maywood | Illinois | 60153 | — |
| Indiana University Health | Indianapolis | Indiana | 46202 | — |
| La Porte County Institute for Clinical Research, Inc. | Michigan City | Indiana | 46360 | — |
| Pulmonary Health Physicians | Fayetteville | New York | 13066 | — |
| Clinical Research of Gastonia | Gastonia | North Carolina | 28054 | — |
| Southeastern Research Center LLC | Winston-Salem | North Carolina | 27103 | — |
| Metroplex Pulmonary and Sleep Center | Allen | Texas | 75013 | — |
| Houston Pulmonary and Sleep Associates | Houston | Texas | 77065 | — |
| Element Research Group | San Antonio | Texas | 78258 | — |
| Renovatio Clinical-Respiratory & Sleep Disorders Specialists | The Woodlands | Texas | 77005 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02722304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02722304 live on ClinicalTrials.gov.